Your browser doesn't support javascript.
loading
DCE-MRI to distinguish all monoclonal plasma cell disease stages and correlation with diffusion-weighted MRI/PET-based biomarkers in a hybrid simultaneous whole body-2-[18F]FDG-PET/MRI imaging approach.
Jamet, Bastien; Necib, Hatem; Carlier, Thomas; Frampas, Eric; Bazin, Juliette; Desfontis, Paul-Henri; Monnet, Aurélien; Bodet-Milin, Caroline; Moreau, Philippe; Touzeau, Cyrille; Kraeber-Bodere, Francoise.
Affiliation
  • Jamet B; Nantes Université, Univ Angers, CHU Nantes, INSERM, CNRS, CRCI2NA, Médecine Nucléaire, F-44000, Nantes, France. bastien.jamet@chu-nantes.fr.
  • Necib H; Nuclear Medicine Department, University Hospital, 1 Place Alexis Ricordeau, 44093, Nantes, France. bastien.jamet@chu-nantes.fr.
  • Carlier T; Nantes Université, Univ Angers, CHU Nantes, INSERM, CNRS, CRCI2NA, Médecine Nucléaire, F-44000, Nantes, France.
  • Frampas E; Nantes Université, Univ Angers, CHU Nantes, INSERM, CNRS, CRCI2NA, Médecine Nucléaire, F-44000, Nantes, France.
  • Bazin J; Nantes Université, Univ Angers, CHU Nantes, INSERM, CNRS, CRCI2NA, Radiologie, F-44000, Nantes, France.
  • Desfontis PH; Nantes Université, Univ Angers, CHU Nantes, INSERM, CNRS, CRCI2NA, Radiologie, F-44000, Nantes, France.
  • Monnet A; Nantes Université, Univ Angers, CHU Nantes, INSERM, CNRS, CRCI2NA, Radiologie, F-44000, Nantes, France.
  • Bodet-Milin C; , Siemens, France.
  • Moreau P; Nantes Université, Univ Angers, CHU Nantes, INSERM, CNRS, CRCI2NA, Médecine Nucléaire, F-44000, Nantes, France.
  • Touzeau C; Nantes Université, Univ Angers, CHU Nantes, INSERM, CNRS, CRCI2NA, Hématologie, F-44000, Nantes, France.
  • Kraeber-Bodere F; Nantes Université, Univ Angers, CHU Nantes, INSERM, CNRS, CRCI2NA, Hématologie, F-44000, Nantes, France.
Cancer Imaging ; 24(1): 93, 2024 Jul 11.
Article in En | MEDLINE | ID: mdl-38992707
ABSTRACT

BACKGROUND:

Dynamic contrast-enhanced-MRI (DCE-MRI) is able to study bone marrow angiogenesis in patients with multiple myeloma (MM) and asymptomatic precursor diseases but its role in the management of MM has not yet been established. The aims of this prospective study was to compare DCE-MRI-based parameters between all monoclonal plasma cell disease stages in order to find out discriminatory parameters and to seek correlations with other diffusion-weighted MRI and positron emission tomography (PET)-based biomarkers in a hybrid simultaneous whole-body-2-[18F]fluorodeoxyglucose (FDG)-PET/MRI (WB-2-[18F]FDG-PET/MRI) imaging approach.

METHODS:

Patients with newly diagnosed Monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM) or symptomatic MM according to international myeloma working group and underwent WB-2-[18F]FDG-PET/MRI imaging including bone marrow DCE sequences at the Nantes University Hospital were prospectively enrolled in this study before receiving treatment.

RESULTS:

One hundred and sixty-seven patients (N = 167, mean age 64 years ± 11 [Standard deviation], 66 males) were considered for the analysis. DCE-MRI-based Peak Enhancement Intensity (PEI), Time to PEI (TPEI) and their maximum intensity time ratio (MITR PEI/TPEI) values were significantly different between the different monoclonal plasma cell disease stages, PEI values increasing and TPEI values decreasing progressively along the spectrum of plasma cell disorders, from MGUS stage to symptomatic multiple myeloma. PEI values were significantly higher in patients with diffuse bone marrow involvement (either in PET or in MRI images) than in those without diffuse bone marrow involvement, unlike TPEI values. PEI and TPEI values were not significantly different between patients with or without focal bone lesions.

CONCLUSION:

Different DCE-MRI-based parameters (PEI, TPEI, MITR) could significantly differentiate all monoclonal plasma cell disease stages and complemented conventional MRI and PET-based biomarkers.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Fluorodeoxyglucose F18 / Diffusion Magnetic Resonance Imaging / Positron-Emission Tomography / Multiple Myeloma Limits: Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Cancer Imaging Journal subject: DIAGNOSTICO POR IMAGEM / NEOPLASIAS Year: 2024 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Fluorodeoxyglucose F18 / Diffusion Magnetic Resonance Imaging / Positron-Emission Tomography / Multiple Myeloma Limits: Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Cancer Imaging Journal subject: DIAGNOSTICO POR IMAGEM / NEOPLASIAS Year: 2024 Document type: Article Affiliation country: